semaglutide eye damage A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Anterior ischemic optic neuropathy in

Gala Health Review blog/Gala Health Review on GLP-1 Compare

This research shows how quickly clinical knowledge is evolving as GLP-1 treatments become part of everyday medical practice across both NHS and private healthcare

F., Dougados, M., & EULAR

doi: 10.1016/j.taap.2017.02.009

UK patients should understand that: Available evidence is largely from Phase 2 studies with relatively short follow-up periods Long-term cardiovascular outcome data are not yet available for either agent Phase 3 trials are ongoing, and results will inform future regulatory submissions to the MHRA UK patients interested in accessing these treatments through clinical trials may wish to consult the NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) or ClinicalTrials.gov for current recruitment opportunities

We are proud to be a trusted part of the Henderson community